The term mood describes a pervasive and sustained
emotional state that may affect all aspects of an individual's life and perceptions.
Mood disorders are pathologically elevated or depressed disturbances
of mood, and include full or partial episodes of depression or mania. A mood episode (for example, major depression) is a cluster of symptoms that
occur together for a discrete period of time.
A major depressive episode involves a depression in mood with an accompanying loss of pleasure or
indifference to most activities, most of the time for at least 2 weeks. These deviations
from normal mood may include significant changes in energy, sleep patterns,
concentration, and weight. Symptoms may include psychomotor agitation or retardation,
persistent feelings of worthlessness or inappropriate guilt, or recurrent thoughts
of death or suicide. The diagnosis of major depression requires
evidence of one or more major depressive episodes occurring without clearly being
related to another psychiatric, AOD use, or medical disorder. Major depression
is subclassified as major depressive disorder, single episode and recurrent. There are nine symptoms of a major depressive episode listed in
the DSM-IV draft, and diagnosis of this disorder requires at least five of
them to be present for 2 weeks.
Dysthymia is a chronic mood
disturbance characterized by a loss of interest or pleasure in most activities of daily
life but not meeting the full criteria for a major depressive episode. The
diagnosis of dysthymia requires mild to moderate mood depression most of the time
for a duration of at least 2 years.
A manic episode is a discrete
period (at least 1 week) of persistently elevated, euphoric, irritable, or expansive
mood. Symptoms may include hyperactivity, grandiosity, flight of ideas, talkativeness,
a decreased need for sleep, and distractibility. Manic episodes, often having
a rapid onset and symptom progression over a few days, generally impair occupational
or social functioning,
and may require hospitalization to prevent harm to self or others. In an extreme
form, people with mania frequently have psychotic hallucinations or delusions.
This form of mania may be difficult to differentiate from schizophrenia
or stimulant intoxication.
A hypomanic episode is a period
(weeks or months) of pathologically elevated mood that resembles but is less severe
than a manic episode. Hypomanic episodes are not severe enough to cause marked
impairment in social or occupational functioning or to require hospitalization.
A bipolar disorder is diagnosed upon evidence of one or more manic
episodes, often in an individual with a history of one or more major depressive episodes.
Bipolar disorder is subclassified as manic, depressed, or mixed, depending
upon the clinical features of the current or most recent episodes. Major depressive
or manic episodes may be followed by a brief episode of the other.
Cyclothymia can be described as a mild form of bipolar disorder, but with more
frequent and chronic mood variability. Cyclothymia includes multiple hypomanic
episodes and periods of depressed mood insufficient to meet the criteria for either
a manic or a major depressive episode. The revised third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) states that
for a diagnosis of cyclothymia to be made, there must be a 2-year period during
which the patient is never without hypomanic or dysthymic symptoms for more than
2 months.
Substance-induced mood disorder is described in
the DSM-IV draft according to the following criteria:
A. A prominent
and persistent disturbance in mood characterized by either (or both) of the
following:
1) depressed mood or markedly diminished interest or pleasure in
all, or almost all, activities,
2) elevated, expansive, or irritable
mood.
B. There is evidence from the history, physical examination,
or laboratory findings of substance intoxication or withdrawal, and the symptoms
in criterion A developed during, or within a month of, significant substance
intoxication or withdrawal.
C. The disturbance is not better accounted for by a mood disorder that is not
substance induced. Evidence that the symptoms are better accounted for by a mood
disorder that is not substance induced might include: the symptoms precede the onset
of the substance abuse or dependence; they persist for a substantial period
of time (e.g., about a month) after the cessation of acute withdrawal or severe
intoxication; they are substantially in excess of what would be expected given the character,
duration, or amount of the substance used; or there is other evidence suggesting
the existence of an independent non-substance-induced mood disorder (e.g.,
a history of recurrent non-substance-related major depressive episodes) .
D. The symptoms cause clinically significant distress or impairment in social,
occupational, or other important areas of functioning.
E. The disturbance does
not occur exclusively during the course of delirium.
Substance-induced
mood disorder can be specified as having 1) manic features, 2) depressive features,
or 3) mixed features. Also, it can be described as having an onset during
intoxication or withdrawal. For most of the major mental illnesses, the DSM-IV draft
includes the alternative of a substance-induced disorder within that diagnosis.
Using structured interviews, the Epidemiologic
Catchment Area (ECA) studies found that nearly 40 percent of people with an alcohol
disorder also fulfilled criteria for a psychiatric disorder. Among people with
other drug disorders, more than half reported symptoms of a psychiatric disorder
(Regier et al., 1990).
The most common psychiatric diagnoses among patients
with an AOD disorder are anxiety and mood disorders. Among those with a mood
disorder, a significant proportion has major depression. Mood disorders may be more
prevalent among patients using methadone and heroin than among other drug users.
In an addiction treatment setting, the proportion of patients diagnosed
with major depression is lower than in a mental health setting.
The prevalence
rates of mood disorders in the general population can be estimated from the results
of the ECA studies (Regier et al., 1988;Robins et al., 1988). These studies
indicate that:
The lifetime prevalence rates for any mood disorder ranged
from 6.1 to 9.5 percent in the ECA study of New Haven, Baltimore, and St. Louis.
The lifetime prevalence rates for major depressive episode ranged from 3.7
to 6.7 percent.
The lifetime prevalence rates for dysthymia ranged
from 2.1 to 3.8 percent.
The lifetime prevalence rates for manic episode
ranged from 0.6 to 1.1 percent.
Some studies demonstrate that
the prevalence of mood and anxiety disorders is no greater among AOD abusers
than in the general population. Other studies show elevated rates of these
disorders among people with AOD disorders. Many patients receiving treatment for
addiction appear depressed, but only a small percent receive a formal diagnosis of
major depression as a concurrent illness.
During the first months of sobriety,
many AOD abusers may exhibit symptoms of depression that fade over time and
that are related to acute withdrawal. Thus, depressive symptoms during withdrawal
and early recovery may result from AOD disorders, not an underlying depression.
A period of time should elapse before depression is diagnosed.
Among
women with an AOD disorder, the prevalence of mood disorders may be high. The
prevalence rate for depression among alcoholic women is greater than the rate among
men. Counselors should be reminded that women in both addiction and nonaddiction
treatment settings are more likely than men to be clinically depressed.
In
addition to women, other populations require special consideration. Native Americans,
patients with HIV, patients maintained on methadone, and elderly people may all
have a higher risk for depression. The elderly may be the group at highest
risk for combined mood disorder and AOD problems. Episodes of mood disturbance
generally increase in frequency with age. Elderly people with concurrent mood and
AOD disorders tend to have more mood episodes as they get older even when their
AOD use is controlled.
Diagnoses of psychiatric disorders
should be provisional and constantly reevaluated. In addiction treatment populations,
many psychiatric disorders are substance-induced disorders that are caused by
AOD use. Treatment of the AOD disorder and an abstinent period of weeks or
months may be required for a definitive diagnosis of an independent psychiatric
disorder. Unfortunately, the severely depressed person may drop out of treatment
or even commit suicide while the clinician is trying to sort things out (see
section on "Assessing Danger to Self or Others.")
Acute manic symptoms may
be induced or mimicked by intoxication with stimulants, steroids, hallucinogens,
or polydrug combinations. They may
also be caused by withdrawal from depressants such as alcohol and by medical
disorders such as AIDS and thyroid problems. Acute mania with its hyperactivity,
psychosis, and often aggressive and impulsive behavior is an emergency and should
be referred to emergency mental health professionals. This is true whatever
the causes may appear to be.
Other psychiatric conditions can mimic mood
disorders. The predominant condition that mimics a mood disorder is addiction, which
is frequently undiagnosed or misdiagnosed. Disorders that can complicate
diagnosis include schizophrenia, brief reactive psychosis, and anxiety disorders.
Patients with personality disorders, especially of the borderline, narcissistic,
and antisocial types, frequently manifest symptoms of mood disorders. These
symptoms are often fluid and may not meet the diagnostic criterion of persistence
over time. In addition, all of the psychiatric disorders noted here can coexist
with AOD and mood disorders.
George is a 37-year-old divorced male who was brought into the emergency room
intoxicated. His blood alcohol level was 152, and the toxicology screen was positive
for cocaine. He was also suicidal ("I'm going to do it right this time! I've
got a gun."). He has a history of three psychiatric hospitalizations and two
inpatient AOD treatments. Each psychiatric admission was preceded by AOD use. George
has never followed through with psychiatric treatment. He has intermittently
attended AA, but not recently.
Mary is a 37-year-old divorced female who
was brought into a detoxification unit with a blood alcohol level of 150 and
was noted to be depressed and withdrawn. She has never used drugs (other than
alcohol), and began drinking alcohol only 3 years ago. However, she has had several
alcohol-related problems since then. She has a history of three psychiatric hospitalizations
for depression, at ages 19, 23, and 32. She reports a positive response to
antidepressants. She is currently not receiving AOD or psychiatric treatment.
Many factors must be examined
when making initial diagnostic and treatment decisions. For example, what if
George's psychiatric admissions were 2 or 3 days long -- usually with discharges
related to leaving against medical advice? Decisions about diagnosis and treatment
would be quite different if two of his psychiatric admissions were 4 to 6 weeks
long with clearly defined manic and psychotic symptoms
continuing throughout the course, despite aggressive use of psychiatric treatment
and medication.
Similarly, what if Mary had abstained from alcohol for
6 months "on her own," but over the past 3 months, she had become increasingly
depressed, tired, and withdrawn, with disordered sleep and poor concentration, as
well as suicidal thoughts? In addition, last night, while planning to kill
herself, she relapsed. A different diagnostic picture would emerge in this case
if Mary had been using antidepressants for the past year and, during the past
month, she had experienced an increase in heavy drinking, losing her job yesterday
because of alcohol use.
It is important to distinguish between mood disorders
and AOD intoxication, withdrawal, and/or chronic effects. These distinctions
are especially important following the chronic use of drugs that cause physiologic
dependence.
All psychoactive drugs cause alterations in normal mood. The severity and
manner of these alterations are regulated by preexisting mood states, type and
amount of drug used, chronicity of drug use, route of drug administration, current
psychiatric status, and history of mood disorders.
AOD-induced mood alterations
can result from acute and chronic drug use as well as from drug withdrawal.
AOD-induced mood disorders, most notably acute depression lasting from
hours to days, can result from sedative-hypnotic intoxication. Similarly, prolonged
or subacute withdrawal, lasting from weeks to months, can cause episodes of
depression, sometimes accompanied by suicidal ideation or attempts.
Also, stimulant
withdrawal may provoke episodes of depression lasting from hours to days, especially
following high-dose, chronic use. Stimulant-induced episodes of mania may include
symptoms of paranoia lasting from hours to days. Overall, the process of addiction
per se can result in biopsychosocial disintegration, leading to chronic dysthymia
or depression often lasting from months to years.
Since symptoms of
mood disorders that accompany acute withdrawal syndromes are often the result
of the withdrawal, adequate time should elapse before a definitive diagnosis
of an independent mood disorder is made.
Conditions that most frequently
cause and mimic mood disorders and symptoms must be differentiated from AOD-induced
conditions. When symptoms persist or intensify, they may represent AOD-induced mental
disorders. Transient dysphoria following the cessation of stimulants can mimic a
depressive
episode. According to the DSM-IV draft, if symptoms are intense and persist for
more than a month after acute withdrawal, a depressive episode can be diagnosed.
Symptoms of shorter duration can be diagnosed as a substance-induced mood
disorder.
It is difficult to generalize about specific drugs causing specific behavioral
syndromes. There is tremendous variability, as demonstrated in Exhibit 5-1. Multiple
drug use further complicates the differential diagnosis. Diagnostic procedures
such as urinalysis and toxicology screens should be used if possible. It should
also be emphasized that addicted patients may experience withdrawal from one
drug despite using another drug.
Stimulants such as cocaine and the amphetamines cause potent psychomotor stimulation. Stimulant intoxication generally includes increased mental and
physical energy, feelings of well-being and grandiosity, and rapid pressured speech.
Chronic, high-dose stimulant intoxication, especially when combined with
sleep deprivation, may prompt an episode of mania. Symptoms may include euphoric,
expansive, or irritable mood, often with flight of ideas, severe impairment of social
functioning, and insomnia.
Acute stimulant withdrawal generally lasts
from several hours to 1 week and is characterized by depressed mood, agitation,
fatigue, voracious appetite, and insomnia or hypersomnia. Depression resulting
from stimulant withdrawal may be severe and can be worsened by the individual's
awareness of addiction-related adverse consequences. Symptoms of craving for stimulants
are likely and suicide is possible.
Protracted stimulant withdrawal often includes sustained episodes of anhedonia and lethargy with frequent
ruminations and dreams about stimulant use. There may be bursts of dysphoria, intense
depression, insomnia, and agitation for several months following stimulant cessation.
These symptoms may be either
worsened or lessened by the quality of the patient's recovery program.
The general effect of the central nervous
system depressants such as alcohol, the benzodiazepines, and the opioids is a
slowing down of an individual's psychomotor processes. However, acute alcohol
intoxication and opioid intoxication often include two phases: an initial
period of euphoria followed by a longer period of relaxation, sedation, lethargy,
apathy, and drowsiness.
Alcohol, barbiturates, and the benzodiazepines can
cause sedative-hypnotic intoxication, especially when taken in high
doses. Psychomotor symptoms include mood lability, mental impairment, impaired
memory and attention, loss of coordination, unsteady gait, slurred speech, and
confusion.
The hallucinogens
can cause a state of intoxication called hallucinosis, which has several features
in common with psychotic disorders and a few in common with mood disorders.
Hallucinogens such as LSD and drugs such as MDMA (methylenedioxy-methamphetamine,
or Ecstasy) and MDA (methylenedioxyamphetamine) may precipitate intense emotional
experiences that may be perceived as positive or negative mood states by the drug user.
These experiences are affected greatly by personality, preexisting mood state,
personal expectations, drug dosage, and environmental surroundings. While many
users will experience sensory and perceptual distortions, some will experience
euphoric religious or spiritual experiences that may resemble aspects of a manic
or psychotic episode. Others may have a deeply troubling introspective experience,
causing symptoms of depression.
Marijuana, which has sedative and psychedelic properties, can cause a variety of mood-related
effects. In the individual who has not developed tolerance for the drug's effects,
high doses of marijuana can cause acute marijuana intoxication with
euphoria or agitation, grandiosity, and "profound thoughts." Together, these symptoms
can mimic mania. Because marijuana is only slowly eliminated from the body,
chronic use results in relatively constant marijuana levels. Thus, daily marijuana
use can be, in effect, a chronic marijuana intoxication. This state
may include symptoms of chronic, low-grade lethargy and depression, perhaps
accompanied by anxiety and memory loss. Phencyclidine (PCP) intoxication
can include symptoms of euphoria, mania, or depression, in addition to sensory
dissociation, hallucinations, delusions, psychotic thinking, altered body image, and
disorientation.
The DSM-IV draft describes diagnostic criteria for mood disorder due to
a general medical condition. The five criteria are:
A. A prominent
and persistent mood disturbance is characterized by either (or both) of the
following:
1) depressed mood or markedly diminished interest or pleasure in
all, or almost all, activities,
2) elevated, expansive, or irritable
mood.
B. There is evidence from the history, physical examination,
or laboratory findings of a general medical condition judged to be etiologically
related to the disturbance.
C. The disturbance is not better accounted for
by another mental disorder (e.g., adjustment disorder with depressed mood,
in response to the stress of having a general medical condition).
D. The symptoms cause clinically significant distress or impairment in social,
occupational, or other important areas of functioning.
E. The disturbance does
not occur exclusively during the course of delirium or dementia.
Mood disorder due to a general medical condition can be described as having
1) manic features, 2) depressive features, or 3) mixed features in which symptoms
of both mania and depression are present and neither predominates.
Medical
conditions that can either precipitate or mimic mood disorders include the following:
Malnutrition
Anemia
Hyper- and hypothyroidism
Dementia
Brain disease
Lupus
HIV/AIDS
Postcardiac condition
Stroke, especially among elderly people.
Medications, including reserpine and other medications that treat hypertension and hypotension,
can cause conditions that may be confused with psychiatric or AOD disorders.
Both prescribed and over-the-counter (OTC) medications can precipitate
depression. Diet pills and other OTC medications can lead to mania. Patients treated
with neuroleptic (antipsychotic) drugs may have a marked constriction of affect
that can be misinterpreted as a symptom of depression.
The patient with coexisting AOD and mood disorders
requires a thorough assessment and treatment for both disorders. The assessment
process can be divided into three clinical phases: acute, subacute, and long term.
Acute and subacute assessment may not be applicable to certain patients seen
in some clinical settings. For instance, AOD treatment program staff in outpatient
settings may see fewer patients with acute psychiatric symptoms than are seen in
detoxification settings.
It is critical to assess whether patients
are threats to themselves or others. This evaluation helps to determine if
there is a duty to protect patients from self-harm, interrupt intentions of violence
toward others, and/or warn intended victims of patients' announced violent intent.
The responsibility to protect some patients from suicide or violence due to
mental illness is not mitigated by confidentiality laws with respect to AOD addiction.
Imminent risk, according to the laws of most States, justifies and requires
commitment of patients or the warning of potential victims.
Generally, AOD confidentiality
laws are very stringent. While some States protect against involuntary commitment
for AOD abuse, they do not protect against commitment for AOD-induced psychiatric
states which involve danger to oneself or others.
Screening personnel should
assess whether suicidal feelings are transitory or reflect a chronic condition.
Consider: Do patients have a suicide plan or serious intentions? Have
they made past attempts? Whether the patients have had prior psychiatric hospitalization
or are in current treatment should be determined. If patients are acutely
dangerous to themselves or others, either voluntary or involuntary methods such as
commitment should be pursued through local resources. AOD staff should have a thorough
knowledge of local resources prior to and in anticipation of crises.
Placement
in a safe holding environment can have a positive effect on patients with
AOD problems and apparent suicidal intentions. If an intake facility cannot
hold such patients, referral to an appropriate facility is recommended. For
example, if someone walks into a program at 8:00 a.m. on Monday saying he wants
to hurt himself, there should be time to talk the person down, assess treatment
needs, and begin treatment or make assessment referrals. When necessary, an assessment
should include a rapid triage. See the sections on the assessment of high-risk
conditions in Chapter 7 (Personality Disorders) and
Chapter 8 (Psychotic Disorders).
In virtually
every recent study of successful or attempted suicide, AOD use and major depression
are among the top associated conditions. Having both conditions simultaneously
leads to even greater risk of suicide.
Patients with manic symptoms that
approach psychotic proportions require thorough evaluation and require urgent care.
Evaluation of mania should be done on a priority basis and should be monitored
during subacute assessments.
Patients who have manic and hypomanic symptoms
often minimize AOD and psychiatric disorders. Because of the symptom of grandiosity,
manic patients may have poor insight into their AOD disorder, their mania, and
their social situation. Manic patients may not see themselves as ill. They
are usually hyperactive and irritable, and often become a danger to themselves
or others through impulsivity, irritability, and poor judgment. When such
people are also intoxicated, most will require involuntary commitment. See
Chapter 8 for a discussion of assessment of patients with psychosis.
Patients, particularly the elderly,
with mood disorders may have life-threatening medical conditions, including
hypoglycemia (insulin overdose), stroke, or infections. These conditions, as well as
withdrawal and toxic drug reactions, must always be considered and require a thorough
physical examination and laboratory assessment. Assessment personnel should make
appropriate referrals for medical assessment and treatment. Facilities that have no
medical component should train assessment staff in triage and referral.
A
plan should be developed to assess and treat medical conditions that precipitate
or complicate mood disturbances. Endocrine disorders (such as thyroid problems),
neurological disorders (such as multiple sclerosis), and HIV infection should be considered.
In addition to obvious medical problems, it can be assumed that basic
medical needs of patients with dual disorders are not being met, and a plan should
be developed to address these deficits.
Clinicians can easily use the
CAGE questions for screening (see Chapter 3) as well
as adapt them for use with patients who may have mood disorders. For example,
consider the following questions adapted from the CAGE questionnaire. "Have you
ever cut down or increased your AOD use related to being severely depressed
(or manic, etc.)?" "Do you ever get more irritable, angry, depressed, or annoyed when using AODs?" "Do you drink or use other drugs to deal with guilt feelings?" "Do you feel more moody in the morning or evening?" "Have
you ever been suicidal when intoxicated?"
Initial AOD assessment should
focus on recent use of alcohol and other drugs and a behavioral history. The
assessor needs to know what drug has been used, in what quantity, with what frequency,
and how recently. Past treatments, past episodes of delirium tremens, hallucinosis,
blackouts, and destructive behavior should be recorded.
The social assessment should evaluate the patient's
social environment, especially in relation to AOD and psychiatric disorders.
It is important to assess whether the patient experiences housing instability
or homelessness. Where does the patient live? Does the patient live in a
home? With whom does the patient live? With whom does the patient have regular
social contact? Are the social and home environments stable?
In the patient's
social life, is there a precipitating crisis occurring? What is the patient's
existing support structure in the home and community? What role do others have?
Is the home free of AODs? Are the home and social environments safe and
free from violence? Do the home and social environments support an abstinent
lifestyle? If not, it should be assessed whether the patient has the support necessary
to overcome the adverse effect of home and social environments that do not
support abstinence and recovery.
During the screening interview, it is important to determine
whether the patient's family members are physically abusive. It should be determined
whether the patient is in danger. Physical and behavioral observation can be an
important aspect of evaluation. The best predictor of future violence is previous
violence.
During AOD use history
taking and psychiatric screening and assessment sessions, patients with AOD disorders
may overemphasize or underemphasize their psychiatric symptoms. For instance,
patients who feel depressed during the assessment may distort their past psychiatric
experiences and unwittingly exaggerate the intensity or frequency of past depressive
episodes.
In contrast, patients who are profoundly depressed during the assessment
may minimize their depressive illness because they think it represents a normal
state. Indeed, some patients may believe that they "deserve" to be depressed,
rather than recognizing that depression is a deviation from normal mood states.
Some patients experience feelings of guilt that are excessive and inappropriate.
Other patients do not accurately label their depression and fail to remember
that they have experienced depression before. Since patients frequently confuse
depression with sadness and other emotions, it is important during the assessment
to ask such questions as: "Have you ever seen a psychiatrist or therapist?"
(If yes: "Why?") "Are you able to get out of bed in the morning or do
you feel chronically tired?" "Have there been any recent changes in your sleeping
patterns or in your appetite?"
Patients may select details from their psychiatric
history consistent with their current mood. Those who are depressed may give a
generally negative self-report. Addicted patients tend to emphasize psychiatric
symptoms; psychiatric patients often underemphasize them. Unhappy addicted patients
in a transient disturbance of mood will often rationalize their histories
as lifelong depression. Thus, it is important to obtain collateral information
from other people and from documents such as medical and psychiatric records.
It is critical to continue the process of evaluation past the period of
drug withdrawal.
Tips for Assessment
The following are sample questions to ask during the
assessment process.
For depression:
"During the past month, has there
been a period of time during which you felt depressed most of the day
nearly every day?"
"During this period of time, did you gain or lose
any weight?"
"Did you have trouble concentrating?"
"Did you
have problems sleeping or did you sleep too much?"
"Did you try to
hurt yourself?"
For mania:
"During the past month,
have you experienced times during which you felt so hyperactive that
you got into trouble or were told by others that your behavior was not normal
for you?"
"Have you recently experienced bouts of irritability during
which you would yell or fight with others?"
"During this period,
did you feel more self-confident than usual?"
"Did you feel pressured
to talk a great deal or feel that your thoughts were racing?"
"Did
you feel restless and irritable?"
"How much sleep do you need?"
Patients' responses to questions are often influenced by the way questions are asked.
Most patients being interviewed tend to say what they believe the interviewer
wants to hear. Therefore, the manner in which the interview is conducted is
important. The interviewer should not lead the patient or make suggestions regarding
the "correct" answer.
Because of the subjective nature of mood disturbances,
the way in which questions are asked is important. Subjective and quantifiable
questions should be asked in an objective way. Neutral, open-ended questions can
be effective. Questions should be asked about impairment and disturbance
of sleep, appetite, and sexual function, as well as other disturbances in
functional impairment. Interviewers must be alert to contradictory responses and
recognize that AOD-dependent patients have a tendency to distort information.
Settings for subacute
assessment include the following:
Medical clinics
Mental health clinics
Sexually transmitted disease (STD) clinics
Hospitals
Emergency
rooms
Welfare and social services offices
Other nontreatment settings
Doctors' offices
Psychotherapists' offices.
This section will
focus on patients who likely have coexisting AOD use and mood disorders, are
not imminently dangerous, and are candidates for treatment. Their functional
levels, liabilities, and strengths should be assessed. The goal of subacute assessment
is to develop treatment plans with less need for the focus on acute protection
(as in the case of acute assessment). Treatment planning is based on a full
assessment of treatment needs.
Assessments can be considered part of the treatment
process since the assessment process often facilitates breaking through the addicted
person's denial mechanisms. By asking specific questions (about work, relationships,
health, or legal problems), the clinician calls attention to the consequences of
AOD use. Toxicology screens and/or abnormal liver function tests such as the
GGT should be obtained when symptoms and AOD use reports don't match. Such
results can be identified as "consequences" of AOD use. Diagnostic and assessment
sessions can be the first intervention. The boundary between assessment and treatment
is fluid.
A plan should be developed to assess and treat medical
conditions that can precipitate or complicate mood disturbances. Such conditions
include endocrine disorders (such as thyroid problems), neurological disorders
(such as multiple sclerosis), and HIV infection.
Some medical problems
may have a heightened visibility because of their more obvious need for ongoing
treatment. However, frequently the primary health care needs of patients with combined
AOD and mood disorders are not pursued. For this reason, a plan to assess
and meet these treatment needs should be developed.
A subacute nonemergency setting is appropriate
for screening and in depth diagnostic interviews for AOD and psychiatric disorders.
The following sources can provide valuable information for screening and
assessment: psychiatric history, previous medical and psychiatric records, and information
from collateral sources such as employers, family members, and laboratory data.
A diagnostic interview, unlike a screening interview, can be done over the
course of several sessions. Collateral sources, especially family members, can
help clarify diagnostic issues and to help patients recognize the denial that
may accompany their disorders.
A thorough history of AOD use, problems,
patterns, and treatments should be obtained at this stage. Such information should
be collected in a supportive nonjudgmental manner and over multiple interviews
when possible. As with the psychiatric assessment, interviews with family and
collateral sources are important.
The diagnostic evaluation can include the clinical application of the DSM-III-R
(or DSM-IV), perhaps in the form of the Structured Clinical Interview from
DSM-III-R (SCID). The Brief Psychiatric Rating Scale, the Hamilton Scale, the Addiction
Severity Index (ASI), and the Beck Scale can also be used to assess patients with
dual disorders.
The SCID and the ASI are research instruments, but their
demonstrated reliability and the advantages of consistent, standardized tools make it
reasonable to administer them. Facilities that use these instruments should provide
training in their use.
A comprehensive psychosocial and vocational assessment
can be an important aspect of the overall assessment. Evaluation of the patient's
ongoing support system is important: What is the patient's support network, including
friends and family? What patterns of interpersonal and family relationships exist
within the nuclear family, the extended family, and the family of choice? What
means of financial support does the patient have? What job skills does the patient
have? Also, both ethnic and cultural backgrounds may alter a person's experience
of both AOD and psychiatric conditions.
Management
of withdrawal is often crucial to patients' safety and comfort. Withdrawal
management can foster patient engagement in an ongoing treatment and recovery process.
Although withdrawal management does not in itself produce enduring abstinence,
it can help to increase retention in the treatment process, which improves
long-term outcome.
Treatment strategies for intoxication range from letting
patients "sleep it off" to confinement in a medical or psychiatric unit. Treatment
for acute sedative-hypnotic withdrawal should include medically managed detoxification.
Hospital settings are preferable, especially for depressed patients.
Opiate withdrawal, while not life threatening, should also be treated medically
and on an inpatient basis when possible. When such hospital-based settings
are unavailable, residential or outpatient support with or without medication
should be attempted.
Since unassisted withdrawal can cause seizure, psychosis,
depression, and suicidal thoughts, it can be dangerous. Thus, successful detoxification
is often a lifesaving process. Also, the medical management of withdrawal
alleviates patients' suffering. It can provide a safe, supportive, and nonthreatening
environment for depressed patients.
Acute treatment may be required for medical conditions identified in the medical
assessment. For example, thyrotoxicosis (thyroid storm) is a life-threatening imitator
of mania. Also, low blood sugar
resulting from insulin overdose can resemble intoxication and depression.
Patients who are imminently
dangerous to themselves or others due to a psychiatric disturbance require emergency
psychiatric treatment. Such treatment may involve voluntary or involuntary confinement.
The presence of a coexisting AOD use disorder or the suspicion
that the psychiatric disturbance is AOD induced does not mitigate requirements
for confinement. Rather, it may necessitate addiction-specific emergency treatment
such as detoxification.
Patients not requiring confinement after evaluation
may benefit from the support of existing family networks, existing programs,
or when available, a rapid referral to a dual disorders treatment program.
Medical management of acute psychiatric symptoms is a treatment strategy during
the acute phase regardless of long-term diagnostic results. Patients who experience
hallucinations, delusions, mania, or significant disorganization of thought can benefit
from medical treatment with antipsychotic medication (such as haloperidol or
thioridazine) whether or not their symptoms are AOD induced. If potentially abusable
medications are required (such as benzodiazepines for acute mania), a period of tapering
or reduction of the medication within 1 or 2 weeks should be built into the
original treatment plan.
During subacute treatment,
the first decision to be made is whether patients should receive treatment
in a psychiatric or addiction setting. In some locations, a third alternative
is available: the dual disorders treatment setting. When realistic, both
types of treatment should be provided simultaneously; integrated treatment generally
is preferable.
Criteria for determining placement include the patient's
treatment needs and potential for loss of control, as well as program features such
as intensity, structure, and limitations. There are also considerations specific
to mood disorders.
For example, if patients are experiencing mania
or psychotic depression with disordered thinking, it must be determined whether
the program is capable of handling and treating patients with these problems.
While psychotic depression or mania is being managed, patients may then
be shifted to an addiction or dual disorder setting. Appropriate matching
of patients to facilities is important.
Some patients with dual disorders
require rare or
minimal psychiatric intervention, such as AOD patients whose bipolar disorder is
successfully managed with lithium and regular blood level monitoring. Patients who
require a strong recovery-oriented AOD abuse treatment program should also receive
treatment for their psychiatric disorder (parallel treatment), with an emphasis on
AOD treatment.
In contrast, patients who experience chronic and severe
psychiatric disturbances and who episodically use AODs in a markedly destructive fashion
will be better treated in a psychiatric program that has staff with expertise
in addiction treatment. The optimal match for the patient with two active
disorders that require treatment is the integrated facility. The intensity of each
disorder dictates the relative intensity of each treatment component required.
Referral to an appropriate facility should be based on practical clinical criteria
rather than on diagnosis alone. For example, patients' ability to understand,
interpret, and tolerate the level of care being provided is most important. Some
patients can participate in standard 12-step groups. Others will require 12-step
groups that are intended for people with dual disorders (Double Trouble groups).
Still others will require professionally run therapy groups that include
patients with similar problems.
Effective treatment is based on what patients
can understand and tolerate, which is not always predicted by diagnosis. Some
psychotic patients function well in traditional programs, while others require special
settings. An individual plan and a flexible ongoing reassessment of effectiveness
are the best ways to ensure fit.
The judicious use of antidepressant and mood-regulating medication
is appropriate for AOD patients with mood disorders. For example, patients
who experience debilitating, misery-provoking, and incapacitating depressive
symptoms may require antidepressant medication to participate in addiction recovery.
(See Chapter 9 for further discussions of psychiatric
medications.)
When depressive symptoms interfere with functioning, antidepressant
medication can provide symptom relief and allow participation in recovery activities
and activities of daily living. Relief from depression and anxiety can be
significant motivating factors in recovery. Left untreated, symptoms can keep patients
from taking part in recovery activities.
Patients who have difficulty
engaging in Alcoholics Anonymous and other support groups and who do not exhibit
evidence of a personality disorder
may be depressed. Depression may manifest as social withdrawal, reclusiveness,
or inability to complete activities of daily living such as going to work.
Regularly spending many hours a day in bed or having serious insomnia
may be cardinal signs of depression but are often seen among patients with
AOD disorders during the first weeks and months of abstinence.
When
prescribing antidepressants for people participating in addiction treatment, the acronym
MASST is a reminder for clinicians of the areas of AOD recovery that need to
be continually assessed. MASST is an acronym that reminds clinicians to assess
patients' treatment needs regarding: 1) Meetings, 2) Abstinence from all psychoactive
drugs, 3) Sponsor (or other helping people), 4) Social support systems, and 5)
overall Treatment efforts. (See the discussion on the use of 12-step programs
in Chapter 6.)
MASST Areas of Recovery
M:
Meetings (12-step or other recovery-oriented self-help)
Case management is crucial when patients
are receiving simultaneous AOD and psychiatric care at separate settings (parallel
treatment). There must be good linkages between the two treatment programs or providers.
For example, patients might see their mental health counselor three times
a week, go to both AOD self-help group meetings and mental health support
group meetings, and receive AOD counseling. This level and mix of treatment can
be overwhelming and confusing for the patient. An effective case manager
can help with planning sensible treatment. Case managers can also facilitate
the use of self-help groups. (See the discussion on the use of 12-step programs
and other self-help groups in Chapter 6).
The separate disorders, their
distinct treatment needs, and the divergent treatment approaches can cause staff
splitting and turf problems that exacerbate the patient's denial and can cause other
treatment problems. These problems can be avoided in almost all cases by effective
communication and coordinated treatment planning. Good psychiatric and addiction treatment
efforts are rarely truly conflicting.
It is beyond the scope of this
TIP to provide comprehensive details on the use of psychotherapeutic treatment.
However, there are numerous resources regarding counseling and psychotherapy
and depression. Recent publications written for both counselors and patients
include The Good News About Depression by M.S. Gold and When Self-Help
Fails by P. Quinnet.
Once psychiatric and addiction severity has been determined, the treatment intensity,
structure, and level of care required must be decided. From the least to the greatest
intensity, the levels of care are:
Individual treatment with a psychotherapist
or counselor. This is the least intensive level of care and includes few,
if any, additional treatment services such as education.
Outpatient
treatment. Within this level of care are services that vary greatly in structure
and intensity. They include weekly to daily individual or group counseling,
often in combination with additional treatment services such as detoxification,
education, medical services, and specially focused groups. A multidisciplinary treatment
team that includes assertive and intensive case management services may be needed
for patients with severe and persistent mood disorders coexisting with AOD
disorders.
Intensive outpatient treatment. This level of care includes treatment models such
as partial hospitalization (which includes day treatment, evening, and weekend
programs). For example, patients in day treatment generally participate in a full
day of treatment for 5 or more days per week. Intensive outpatient treatment
represents a range of treatment intensities. The level of intensity of a given program
is based primarily on the number of treatment services offered. Generally,
intensive outpatient treatment programs offer several treatment components such as
group therapy, educational sessions, and social support services.
Halfway
houses. These are settings that serve as safe AOD-free homes for people who can
manage independent daily activities and can benefit from a structured and recovery-oriented
group living arrangement. They vary widely in style and purpose.
Residential
rehabilitation setting. Participation can vary from 30 days to 3 months or more, with
patients removed from familiar surroundings and
separated from AODs. In residential settings, patients receive education about dual
disorders and learn important recovery skills such as utilizing groups, building
trust, and talking about feelings. Therapy and support groups provide socialization
and support and are the core of treatment. They prepare the patient for increased
reliance on group support systems after discharge.
Therapeutic communities.
Long-term therapeutic communities often require patient participation
lasting from 6 months to 2 years. They are generally considered to be appropriate
for patients with severe AOD disorders who have significant social and vocational
deficits and who require long-term and intensive support, skill building, interpersonal
abilities refinement, and trauma resolution.
Hospitals. Psychiatric or AOD
hospitalization may be required for acute and subacute stabilization. In this age of managed
care, hospitalization episodes have become much shorter and more acute than a
few years ago. This puts more responsibility and risk on outpatient treatment
providers.
Patients with severe and persistent mood and AOD disorders frequently require intensive
and assertive treatment approaches as outlined in Chapter 8 on psychotic disorders.
These patients will benefit from programs that can provide concurrent,
integrated dually focused treatment. Also, these patients may require assertive case
management to encourage medication compliance and to help them secure all psychiatric,
addiction, and social services that they may need.
While some programs for dual
disorders exist at all levels of care and in several program models, few AOD or mental
health residential programs are dually focused, and many AOD programs refuse to
accept patients who have histories of psychiatric disorders or who currently are
prescribed medication for psychiatric disorders.
Traditional biases in the addiction
field against psychiatric medication should be shed in light of the evidence
that medicating existing disorders is humane, can be provided safely, and is
necessary for some patients to engage in treatment. It is helpful to use psychiatrists
who are skilled and are perhaps specialists in the treatment of coexisting
psychiatric and AOD disorders.
Similarly, traditional psychiatric biases regarding
rapid medication intervention and some clinicians' emphases on "getting in touch
with feelings" can impede or reverse the AOD recovery process. Encouraging emotional
expression without regard for the patient's stage of AOD recovery and stability can
aggravate AOD disorders. Many residential facilities in the mental health system
are inadequately controlled for the presence of AODs, are not abstinence based,
and are not safe environments for AOD users.
In all of the above settings,
patients should receive family therapy and education, addiction and recovery counseling,
and psychiatric counseling. Special attention must be focused on the chronic
and cyclical nature of addiction and mood disorders and the likelihood of relapse.
Manic patients' uncontrolled grandiose behaviors have frequently caused their
families great stress. Thus, family members need education about the nature of
addiction, mania, and recovery. It is necessary for staff to ally with family members
to ensure cooperation with treatment and reduce collusion between family members
and the patient.
Similarly, the depressed patient is frequently seen
as a family burden. Families need assistance to engage the depressed patient.
The combination of depression and addiction can be very difficult for
family members, and the challenges for the family must be considered.
Family
and friends are often mistakenly afraid that they might exacerbate or aggravate
depression or mania if they confront the dangerous and maladaptive behaviors and denial
that result from addiction and mood disorders. Such fears are ungrounded.
In fact, supportive intervention by the patient's social network is helpful
with respect to both disorders.
The patient's family should be encouraged
to confront the patient rather than remain reticent, and they should be coached
to confront the patient in a supportive way. Support for and education of
family members are necessary to encourage their constructive involvement and to
help them avoid collusion in the patient's drug-using behavior or denial of
psychiatric disturbance.
While some patients with dual disorders have severe and poorly remitting mood
and AOD disorders, most patients improve, especially with careful psychiatric
treatment. Since these disorders are generally well controlled, patients can experience
very high levels of vocational, social, and creative functioning. As a result,
vocational planning should be long term and accentuate patient strengths.
Studies demonstrate that HIV/AIDS risk
reduction measures can make a difference in the rate of HIV infection. Potential
and actual risk behaviors that are identified in evaluation should be addressed
by referral to specific educational, training, and intervention programs.
Staff at these programs should be sensitive to patients' cultural
and ethnic backgrounds, and understand how these can influence AOD use, sexual
behaviors, and patients' receptivity to risk reduction measures. Programs should
be proficient in communicating with patients using culturally sensitive language.
However, the most culturally insensitive position is to avoid raising
these issues out of fear or hesitancy.
With respect to risk reduction,
special attention should be paid to the fact that, while depressed, many patients
may be sexually abstinent, but this behavior may not reflect their typical
behavior patterns. If patients are assessed while they are depressed, they should
be asked to describe their sexual behavior during times when not depressed,
or perhaps they should be assessed when they are not depressed. Mania and
active AOD use markedly elevate the potential for high-risk behaviors and should
be seen as extremely dangerous situations for the transmission of HIV and
other sexually transmitted diseases.
HIV counseling and testing is appropriate
and advisable for patients with coexisting AOD and mood disorders. There is
no evidence that people with mood disorders become suicidal or experience
thought disorganization in response to HIV testing.
Treatment goals should include consolidating the
AOD-free lifestyle, establishing psychiatric stability, achieving social independence
and stability, and enhancing vocational choices and goals. Long-term treatment
can be viewed as a maintenance period -- a time for personal growth and development
and consolidation of long-term, satisfying patterns of social adaptation.
The long-term management of addiction
includes participation in 12-step programs and other support groups, individual
and group counseling, and in some cases, continued participation in a treatment
program. The severity of a patient's illness should be matched with the appropriate
treatment intensity and level of care.
Patients with dual disorders who experience
low
levels of psychiatric impairment require a level of care that can be provided
in traditional low-structure abstinence-oriented addiction treatment programs.
Dual disorder patients who experience severe psychiatric symptoms or cognitive
impairment require a more intense level of care such as that provided by a highly
structured dual disorders treatment program. Matching patients to the appropriate
treatment and level of care can help achieve desired outcomes.
The majority of patients receiving treatment for combined
mood disorders and addiction improve in response to treatment. When they don't
improve, there should be a reevaluation of the treatment plan. For example, a patient
receiving antidepressant medication who is abstinent from AODs but anhedonic (unable
to feel pleasure or happiness) requires a careful evaluation and assessment
to identify resistant psychiatric conditions that require treatment. In this
example, based on assessment, an additional treatment service such as psychotherapy
may be added. Indeed, psychotherapy has been shown to improve the efficacy
of addiction treatment and of psychiatric treatment that involves antidepressant
medication.
When patients do not improve as expected, it is not necessarily because of treatment
failure or patient noncompliance. Patients may be compliant and plans may be adequate,
but disease processes remain resistant. Persistent attention to the addictive
process and its complications as well as meticulous attention to psychiatric therapy
usually leads to improvement. However, patients with severe and persistent AOD
and mood disorders should not be seen as resistant, manipulative, or unmotivated
but as extremely ill and requiring intensive treatment.
Patients who have experienced sexual, physical,
or psychological abuse may have problems that surface during acute treatment
or that are identified during long-term treatment evaluations. Treatment
needs resulting from these types of abuse should be addressed in the long-term
treatment plan.
The resolution of problems related to sexual, physical, and
psychological abuse usually requires specialized, long-term treatment. However, these
problems should be addressed whenever they surface in any phase of treatment for
AOD and mood disorders.
For example, addressing these problems during
early recovery should be viewed from the perspective
of anxiety reduction and consolidation of abstinence. At that phase of recovery,
the treatment goal is to have patients contain or express their potent and
surfacing feelings without using alcohol and other drugs. Later in recovery, these
problems can be dealt with in terms of long-term stabilization and psychological
resolution.
Continuing addiction counseling and participation in group support activities are
useful to help consolidate abstinence. These recovery maintenance activities
include participation in social clubs, 12-step programs, religious organizations,
and other cultural institutions. Community-based activities can provide long-term
stability to these patients.
At this stage of treatment, special treatment
needs can be identified through targeted testing in such areas as neurologic,
cognitive, and personality disorders. Special treatment needs should be specifically
addressed by the appropriate treatment strategy. STD and HIV risk reduction, evaluated
throughout the progression of illness, should now address the importance of long-term
stable changes in behavior.
Family members should be evaluated for AOD problems in acute and subacute stages
when the family members begin to become involved in the patient's treatment.
There is usually adequate time to deal with family issues in the subacute
phase, when personnel and family members become acquainted. Family members include
household members as well as members of the patient's support system.
The family
often needs and should receive treatment. After careful evaluation of family
dynamics, the presence of addictive disorders or codependent behavior in the family
should be evaluated. The presence of AOD and mood disorders in the patient is
the best predictor of AOD and mood disorders in the family. A family history
of one disease increases the risk for the other; a family history of both
disorders multiplies the risk factor.
Family therapy can be provided on site.
Individual family members should be referred for the treatment of specific
problems when required. It is often necessary to help families "mop up the rage"
that has accumulated. It is important to determine when to deal with the family
as a group to resolve conflicts and when members need to work with a therapist
alone to develop independence from dysfunctional reliance. Participation in
Al-Anon and related self-help groups for family members should be encouraged and
incorporated in the treatment schedule for family members.
Other conditions that coexist with dual
disorders include eating disorders and pathologic gambling. It may be helpful to
refer patients to support groups that deal with these conditions. Eating disorders
are more commonly diagnosed in women, and pathologic gambling is more commonly
diagnosed in men.
The purposes of ongoing reassessments are: 1) to continue to refine
prior diagnostic assessments, 2) to evaluate life adjustment in general, 3) to
evaluate the effectiveness of treatment efforts for the dual disorders, and 4) to
evaluate the discontinuation or
continued use of medication and other treatments.
Persistently emerging and
remitting problems should be addressed. For example, patients who chronically exhibit
a negative disposition should be assessed for a personality disorder. Such
patients may have a personality disorder with depressive features rather than a
mood disorder.
Specific neuropsychological,
psychological, educational, and vocational testing assessments should be performed when
necessary and appropriate. These include testing for learning disorders, cognitive
or literacy impairments, and personality disorders. These tests are more
reliable and accurate when performed following several months of sobriety.